Accuray Q3 2024 GAAP EPS $(0.06) Misses $(0.01) Estimate, Sales $101.132M Miss $113.649M Estimate

5/1/24 5:31:57 PM ET

Medical/Dental Instruments

Health Care

Get the next $ARAY alert in real time by email

Accuray (NASDAQ:ARAY) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 700 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $101.132 million which missed the analyst consensus estimate of $113.649 million by 11.01 percent. This is a 14.34 percent decrease over sales of $118.060 million the same period last year.

Get the next $ARAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARAY

Date	Price Target	Rating	Analyst
2/13/2024	$9.00	Buy	ROTH MKM
6/23/2022	$7.50	Buy	B. Riley Securities
12/22/2021	$7.50	Buy	Loop Capital

More analyst ratings

$ARAY
Financials

Live finance-specific insights

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 6, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
10/23/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
8/14/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa
7/31/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care

Accuray Appoints Michael Murphy as VP, Corporate Controller
MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024
10/21/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Robert C. Kill Joins Accuray Board of Directors
SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie
2/1/23 4:10:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
12/6/22 8:00:00 AM ET
$ARAY
$EDAP
$HPQ
$INTC
Medical/Dental Instruments
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Computer Manufacturing

$ARAY
Press Releases

Fastest customizable press release news feed in the world

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 6, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
10/23/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray Appoints Michael Murphy as VP, Corporate Controller
MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024
10/21/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer
The Precision of Stereotactic Body Radiation Therapy (SBRT), an Advanced Treatment Technique, Enables Treatment in Five Days, Significantly Reducing the Time Men Must Spend Undergoing Care MADISON, Wis., Oct. 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that results of the PACE-B – Prostate Advances in Comparative Evidence – trial were published in the New England Journal of Medicine (NEJM). The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy (CRT), while reducing the overall treatment
10/17/24 7:00:00 AM ET
$ARAY
Medical/Dental Instruments
Health Care

Accuray Q3 2024 GAAP EPS $(0.06) Misses $(0.01) Estimate, Sales $101.132M Miss $113.649M Estimate

Chat with this insight

Recent Analyst Ratings for $ARAY

$ARAY Financials

Live finance-specific insights

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024

$ARAY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 3,207 shares, decreasing direct ownership by 0.81% to 390,931 units (SEC Form 4)

Senior VP Global Operations Hoge Michael covered exercise/tax liability with 8,102 shares, decreasing direct ownership by 2% to 382,106 units (SEC Form 4)

President Winter Suzanne C covered exercise/tax liability with 16,604 shares, decreasing direct ownership by 1% to 1,336,476 units (SEC Form 4)

$ARAY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Accuray with a new price target

B. Riley Securities initiated coverage on Accuray with a new price target

Loop Capital initiated coverage on Accuray with a new price target

$ARAY Leadership Updates

Live Leadership Updates

$ARAY Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ARAY Market Insights

Live Market Insights

Accuray Appoints Michael Murphy as VP, Corporate Controller

Robert C. Kill Joins Accuray Board of Directors

EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary

Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System

Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities

Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

$ARAY SEC Filings

Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Accuray Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Accuray Incorporated

$ARAY Press Releases

Fastest customizable press release news feed in the world

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Appoints Michael Murphy as VP, Corporate Controller

New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer

$ARAY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

SEC Form SC 13G filed by Accuray Incorporated

SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

Recent Analyst Ratings for
$ARAY

$ARAY
Financials

$ARAY
Insider Trading

$ARAY
Analyst Ratings

$ARAY
Leadership Updates

$ARAY
Insider Purchases

$ARAY
Market Insights

$ARAY
SEC Filings

$ARAY
Press Releases

$ARAY
Large Ownership Changes